Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 3
2018 1
2019 2
2020 3
2021 4
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Serine Is an Essential Metabolite for Effector T Cell Expansion.
Ma EH, Bantug G, Griss T, Condotta S, Johnson RM, Samborska B, Mainolfi N, Suri V, Guak H, Balmer ML, Verway MJ, Raissi TC, Tsui H, Boukhaled G, Henriques da Costa S, Frezza C, Krawczyk CM, Friedman A, Manfredi M, Richer MJ, Hess C, Jones RG. Ma EH, et al. Among authors: boukhaled g. Cell Metab. 2017 Feb 7;25(2):345-357. doi: 10.1016/j.cmet.2016.12.011. Epub 2017 Jan 19. Cell Metab. 2017. PMID: 28111214 Free article.
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy.
Boukhaled GM, Gadalla R, Elsaesser HJ, Abd-Rabbo D, Quevedo R, Yang SYC, Guo M, Wang BX, Noamani B, Gray D, Lau SCM, Taylor K, Aung K, Spreafico A, Hansen AR, Saibil SD, Hirano N, Guidos C, Pugh TJ, McGaha TL, Ohashi PS, Sacher AG, Butler MO, Brooks DG. Boukhaled GM, et al. Nat Immunol. 2022 Aug;23(8):1273-1283. doi: 10.1038/s41590-022-01262-7. Epub 2022 Jul 14. Nat Immunol. 2022. PMID: 35835962
Opposing Roles of Type I Interferons in Cancer Immunity.
Boukhaled GM, Harding S, Brooks DG. Boukhaled GM, et al. Annu Rev Pathol. 2021 Jan 24;16:167-198. doi: 10.1146/annurev-pathol-031920-093932. Epub 2020 Dec 2. Annu Rev Pathol. 2021. PMID: 33264572 Free PMC article. Review.
Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection.
Snell LM, Xu W, Abd-Rabbo D, Boukhaled G, Guo M, Macleod BL, Elsaesser HJ, Hezaveh K, Alsahafi N, Lukhele S, Nejat S, Prabhakaran R, Epelman S, McGaha TL, Brooks DG. Snell LM, et al. Among authors: boukhaled g. Nat Immunol. 2021 Dec;22(12):1524-1537. doi: 10.1038/s41590-021-01060-7. Epub 2021 Nov 18. Nat Immunol. 2021. PMID: 34795443 Free PMC article.
Molecular, metabolic and functional CD4 T cell paralysis impedes tumor control.
Guo M, Abd-Rabbo D, Bertol B, Carew M, Lukhele S, Snell LM, Xu W, Boukhaled GM, Elsaesser H, Halaby MJ, Hirano N, McGaha TL, Brooks DG. Guo M, et al. Among authors: boukhaled gm. bioRxiv [Preprint]. 2023 Apr 17:2023.04.15.536946. doi: 10.1101/2023.04.15.536946. bioRxiv. 2023. PMID: 37131587 Free PMC article. Updated. Preprint.
IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B.
Chua C, Salimzadeh L, Ma AT, Adeyi OA, Seo H, Boukhaled GM, Mehrotra A, Patel A, Ferrando-Martinez S, Robbins SH, La D, Wong D, Janssen HLA, Brooks DG, Feld JJ, Gehring AJ. Chua C, et al. Among authors: boukhaled gm. Hepatol Commun. 2023 Dec 7;7(12):e0337. doi: 10.1097/HC9.0000000000000337. eCollection 2023 Dec 1. Hepatol Commun. 2023. PMID: 38055623 Free PMC article.
18 results